foxo4-dri senolytic peptide study 2017 Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells Development of a novel senolytic

Products are sold for research use only (RUO), are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S

[DOI] [PubMed] [Google Scholar] 19.Shilleh A.H., Viloria K., Broichhagen J., Campbell J.E., Hodson D.J

Gowen et al , 2017

Layer 1 Identity confirmation by mass spectrometry: a simple MALDI-TOF or ESI-MS measurement on a reconstituted aliquot confirms the expected molecular mass (1419.55 Da theoretical, observed [M+H]+ at m/z 1420.5 or related adducts)

Conclusion The promotion and prescription of BPC-157 for musculoskeletal injuries without FDA approval is a troubling trend that poses significant risks to patients